Bifogade filer
Kurs
-8,66%
Likviditet
425 MDKK
Kalender
Tid* | ||
2025-11-14 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-08-22 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-05-09 | 07:30 | Kvartalsrapport 2025-Q1 |
2025-04-09 | N/A | Årsstämma |
2025-03-05 | 08:00 | Bokslutskommuniké 2024 |
2024-11-15 | - | Kvartalsrapport 2024-Q3 |
2024-08-22 | - | Kvartalsrapport 2024-Q2 |
2024-05-08 | - | Kvartalsrapport 2024-Q1 |
2024-04-17 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2024-04-16 | - | Årsstämma |
2024-03-06 | - | Bokslutskommuniké 2023 |
2023-11-16 | - | Kvartalsrapport 2023-Q3 |
2023-08-23 | - | Kvartalsrapport 2023-Q2 |
2023-05-09 | - | Kvartalsrapport 2023-Q1 |
2023-03-31 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2023-03-30 | - | Årsstämma |
2023-03-02 | - | Bokslutskommuniké 2022 |
2022-11-09 | - | Kvartalsrapport 2022-Q3 |
2022-08-24 | - | Kvartalsrapport 2022-Q2 |
2022-05-09 | - | Kvartalsrapport 2022-Q1 |
2022-04-06 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2022-04-05 | - | Årsstämma |
2022-03-04 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-25 | - | Kvartalsrapport 2021-Q2 |
2021-05-27 | - | Kvartalsrapport 2021-Q1 |
2021-04-21 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2021-04-20 | - | Årsstämma |
2021-03-12 | - | Bokslutskommuniké 2020 |
2020-11-11 | - | Kvartalsrapport 2020-Q3 |
2020-08-26 | - | Kvartalsrapport 2020-Q2 |
2020-06-15 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2020-06-12 | - | Årsstämma |
2020-05-14 | - | Kvartalsrapport 2020-Q1 |
2020-02-20 | - | Bokslutskommuniké 2019 |
2019-11-27 | - | Extra Bolagsstämma 2019 |
2019-11-07 | - | Kvartalsrapport 2019-Q3 |
2019-08-15 | - | Kvartalsrapport 2019-Q2 |
2019-04-25 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2019-04-24 | - | Årsstämma |
2018-04-18 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2018-04-17 | - | Årsstämma |
2017-04-26 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2017-04-25 | - | Årsstämma |
2016-04-21 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2016-04-20 | - | Årsstämma |
2015-04-24 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2015-04-23 | - | Årsstämma |
2014-04-25 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2014-04-24 | - | Årsstämma |
2013-04-18 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2013-04-17 | - | Årsstämma |
2012-04-17 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2012-04-16 | - | Årsstämma |
2011-04-27 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
2011-04-26 | - | Årsstämma |
2010-04-28 | - | X-dag ordinarie utdelning BAVA 0.00 DKK |
Beskrivning
Land | Danmark |
---|---|
Lista | Large Cap Copenhagen |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
COPENHAGEN, Denmark, September 5, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 7,164,460 as a consequence of employees’ exercise of warrants.
The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 447,869 shares at DKK 146.60, 7,039 shares at DKK 155.80 and 261,538 shares at DKK 206.82. The total proceeds to Bavarian Nordic A/S from the capital increase amounts to DKK 120.8 million.
The new shares, which will rank pari passu in all respects with existing Bavarian Nordic shares, will be admitted to trading and official listing on Nasdaq Copenhagen as soon as possible.
After the capital increase, the total nominal value of Bavarian Nordic A/S' share capital is DKK 788,329,820, which is made up of 78,832,982 shares of a nominal value of DKK 10 each, corresponding to 78,832,982 votes.
The revised Articles of Association will be published shortly on the Company's website.
The content of this announcement does not affect the Company’s expectations for the financial results for 2024.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, supplied to governments to enhance public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. For more information visit www.bavarian-nordic.com.
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 44
US: Graham Morrell, graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 27 / 2024